Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00526838 · ClinicalTrials.gov registry record · Phase 1
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT00526838: Clinical Trial Phase 1 study, sponsored by Exelixis.
NCT00526838 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 84 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00526838, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous infusion in subjects with advanced malignancies.
Interventions
- DRUG XL228
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Why NCT00526838 stopped before completion
NCT00526838 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher).
The record links to 0 conditions, and to 1 intervention - of which XL228 is the first listed.
NCT00526838 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00526838 about?
NCT00526838 is a clinical study titled "Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies". The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous infusion in subjects with advanced malignancies.
What is the current status of trial NCT00526838?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2007-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00526838?
The interventions under investigation include: XL228 (DRUG).
Who is sponsoring clinical trial NCT00526838?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00526838's enrollment target sits among peer trials
84 659th of 2000 higher than 1,336 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia